Investment analysts at StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a note issued to investors on Monday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Performance
Shares of Titan Pharmaceuticals stock opened at $5.48 on Monday. The business has a 50 day moving average of $5.89 and a 200 day moving average of $6.35. Titan Pharmaceuticals has a 52 week low of $4.24 and a 52 week high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last announced its earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) EPS for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Stories
- Five stocks we like better than Titan Pharmaceuticals
- What is a Low P/E Ratio and What Does it Tell Investors?
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- Canadian Penny Stocks: Can They Make You Rich?
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Consumer Discretionary Stocks Explained
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.